BCR and diffuse large B-cell lymphoma: Emerging insights from multi-omics profiling have unveiled distinct molecular mechanisms within DLBCL, including dysregulated B-cell receptor (BCR) signaling, epigenetic reprogramming, and immune checkpoint dysregulation, necessitating a shift from histomorphology-driven to genotype-guided therapeutic strategies.